$ News

Acelyrin, Inc. (SLRN): One of the Best Short-Term Stocks to Buy Right Now

ACELYRIN Adopts Limited-Duration Stockholder Rights Plan

Acelyrin: Potential Buyout Led By Concentra Biosciences

Is Acelyrin, Inc. (SLRN) the Best Micro Cap Stock to Buy Now?

Sector Update: Health Care Stocks Lower Tuesday Afternoon

Ozempic, Wegovy shortage resolved; Pfizer CEO is PhRMA’s new chair

ACELYRIN, INC. Announces Additional Phase 2 Data and Phase 3 Program Design for Lonigutamab in Thyroid Eye Disease

ACELYRIN, INC. to Host Virtual Investor Event to Share new Phase 2 Data and Phase 3 Program Design for Subcutaneous Lonigutamab

ACELYRIN, INC. Announces Topline Results From Phase 2b/3 Study of Izokibep for the Treatment of Uveitis

Acelyrin: Abandoned Programs Do Not Give Confidence

Acelyrin Inc (SLRN) Q3 2024 Earnings Call Highlights: Strategic Pipeline Refocus and Financial ...

Acelyrin, Inc. (SLRN) Q3 2024 Earnings Call Transcript

ACELYRIN, INC. Reports Third Quarter 2024 Financial Results and Recent Highlights

ACELYRIN, INC. to Report Third Quarter 2024 Financial Results and Corporate Update on November 13, 2024

ACELYRIN, INC. Forms Scientific and Patient Advisory Board Featuring Leading Voices in Thyroid Eye Disease

Acelyrin forms scientific, patient advisory board

Acelyrin price target raised by $2 at Wells Fargo, here's why

Promising Outlook for ACELYRIN’s Izokibep in Uveitis Treatment Drives Buy Recommendation

Acelyrin spikes as late-stage data for lead asset selected for medical event

ACELYRIN, INC. Announces Positive Results from Global Phase 3 Clinical Trial of Izokibep in Hidradenitis Suppurativa to be Highlighted in Late-Breaking Oral Presentation at EADV 2024